ScripIt is well known that the pharmaceutical industry is unpredictable. Both drug developers themselves and the brokers covering them must do their best to try and predict the performance of their assets
ScripWhen clinical trial details are teased but deferred, investors will take a steer from the company management and key opinion leader commentaries. This has the potential for bias. Recent events around
ScripBridgeBio Pharma’s Attruby (acoramidis) delivered $36.7m in sales during the first quarter of 2025 – three times analyst consensus of $12m for the transthyretin amyloidosis with cardiomyopathy (ATTR-C
ScripThe hemophilia market is a challenging and competitive field but Sanofi is confident that fitusiran, which has just been given the green light by the US Food and Drug Administration (28 March), has th